Compound Evidence File
#EC-2026-0363
Semaglutide Oral
Filed under Oral Tablets. The bureau holds 140 laboratory returns for this compound from 46 distinct subjects. Scores below are per-subject aggregates; open a subject row for the underlying evidence.
Cross-Index
Subjects Shipping This Compound
46 SUBJECTS| Subject | Grade | Samples | Mean | Min | Max | First seen | Last seen |
|---|---|---|---|---|---|---|---|
| HomopeptideCASE #VI-2026-0760 | A | 6 | 10.0 | 9.9 | 10.0 | 23 May 2026 | 23 May 2026 |
| Tianjin Finder Chemical TFCCASE #VI-2026-0693 | A | 5 | 10.0 | 10.0 | 10.0 | 14 Nov 2025 | 16 Apr 2026 |
| Shanghai ERP BiotechnologyCASE #VI-2026-0936 | A | 4 | 10.0 | 10.0 | 10.0 | 18 Apr 2026 | 5 Jul 2026 |
| QYAOBIOCASE #VI-2026-0861 | A | 4 | 10.0 | 9.9 | 10.0 | 6 Jan 2026 | 3 Jul 2026 |
| JEEP PeptidesCASE #VI-2026-0457 | A | 4 | 10.0 | 9.9 | 10.0 | 20 Mar 2026 | 8 Jul 2026 |
| Hubei JianxiangCASE #VI-2026-0048 | A | 4 | 10.0 | 10.0 | 10.0 | 18 Mar 2026 | 1 Jul 2026 |
| Flourishglobal PeptideCASE #VI-2026-0630 | A | 4 | 10.0 | 9.9 | 10.0 | 5 Nov 2025 | 17 Jun 2026 |
| Sangon BioCASE #VI-2026-0671 | A | 3 | 10.0 | 9.9 | 10.0 | 15 Mar 2026 | 15 Jun 2026 |
| WuXi TIDESCASE #VI-2026-0335 | A | 3 | 10.0 | 9.9 | 10.0 | 20 Jan 2026 | 11 Apr 2026 |
| Mokemei BiotechnologyCASE #VI-2026-0540 | A | 2 | 10.0 | 10.0 | 10.0 | 9 Apr 2026 | 11 May 2026 |
| HazelCASE #VI-2026-0392 | X | 1 | 10.0 | 10.0 | 10.0 | 13 Jun 2025 | 13 Jun 2025 |
| BachemCASE #VI-2026-0314 | A | 4 | 9.9 | 9.9 | 10.0 | 11 Mar 2026 | 13 Jul 2026 |
| Kerui PeptidesCASE #VI-2026-0626 | A | 4 | 9.9 | 9.9 | 10.0 | 25 Nov 2025 | 22 May 2026 |
| Shanghai Wibson BiotechnologyCASE #VI-2026-0379 | A | 4 | 9.9 | 9.9 | 10.0 | 6 Nov 2025 | 13 Jul 2026 |
| Shanghai Sigma AudleyCASE #VI-2026-0505 | A | 4 | 9.9 | 9.9 | 10.0 | 28 Apr 2026 | 23 Jun 2026 |
| Chinese Peptide CompanyCASE #VI-2026-0184 | A | 2 | 9.9 | 9.9 | 10.0 | 1 Apr 2026 | 19 Jun 2026 |
| Nantong Guangyuan Chemical GYCCASE #VI-2026-0284 | A | 4 | 9.4 | 8.2 | 10.0 | 24 May 2026 | 24 May 2026 |
| Shanghai Sigma Audley SSACASE #VI-2026-0486 | A | 7 | 8.7 | 7.3 | 10.0 | 24 May 2026 | 24 May 2026 |
| Wuhan Wansheng Bio (WWB)CASE #VI-2026-0594 | A | 8 | 8.4 | 7.4 | 8.9 | 24 May 2026 | 24 May 2026 |
| Glbiochem (Shanghai)CASE #VI-2026-0704 | A | 5 | 8.4 | 7.2 | 9.3 | 25 May 2026 | 25 May 2026 |
| Qingdao Sigma Chemical QSCCASE #VI-2026-0538 | A | 4 | 8.4 | 7.9 | 9.0 | 24 May 2026 | 24 May 2026 |
| HealthTide BiotechCASE #VI-2026-0955 | X | 1 | 8.3 | 8.3 | 8.3 | 25 Apr 2025 | 25 Apr 2025 |
| ScienceCASE #VI-2026-0636 | X | 1 | 7.4 | 7.4 | 7.4 | 6 May 2025 | 6 May 2025 |
| Shenzhen Jiechuang TradingCASE #VI-2026-0292 | X | 1 | 7.4 | 7.4 | 7.4 | 3 Jul 2025 | 3 Jul 2025 |
| Simple PeptideCASE #VI-2026-0782 | X | 1 | 7.4 | 7.4 | 7.4 | 2 Apr 2025 | 2 Apr 2025 |
| ZLZ PeptideCASE #VI-2026-0524 | X | 13 | 7.3 | 4.6 | 9.9 | 3 Jul 2025 | 19 Jan 2026 |
| Shenzhen Loga Tech LG LOGACASE #VI-2026-0920 | X | 1 | 7.3 | 7.3 | 7.3 | 16 Mar 2025 | 16 Mar 2025 |
| Kits4lessCASE #VI-2026-0744 | X | 1 | 7.2 | 7.2 | 7.2 | 20 Jun 2025 | 20 Jun 2025 |
| Prime PeptidesCASE #VI-2026-0696 | X | 1 | 6.9 | 6.9 | 6.9 | 21 May 2025 | 21 May 2025 |
| Limitless Life NootropicsCASE #VI-2026-0980 | X | 1 | 6.8 | 6.8 | 6.8 | 14 Jan 2025 | 14 Jan 2025 |
| LiliPeptideCASE #VI-2026-0695 | X | 6 | 6.7 | 4.1 | 9.3 | 13 Jun 2025 | 26 Jan 2026 |
| InjectifyCASE #VI-2026-0387 | X | 1 | 6.6 | 6.6 | 6.6 | 6 May 2025 | 6 May 2025 |
| TSC Top Supplements ChinaCASE #VI-2026-0523 | X | 9 | 6.5 | 4.5 | 8.6 | 17 Dec 2024 | 24 May 2026 |
| Shanghai BaojuCASE #VI-2026-0233 | X | 1 | 6.5 | 6.5 | 6.5 | 9 Jun 2025 | 9 Jun 2025 |
| HkRoidsCASE #VI-2026-0784 | X | 1 | 6.5 | 6.5 | 6.5 | 16 Mar 2025 | 16 Mar 2025 |
| Top PeptideCASE #VI-2026-0721 | X | 2 | 6.4 | 6.3 | 6.6 | 27 Feb 2025 | 23 May 2026 |
| Evolve BioPepCASE #VI-2026-0755 | X | 1 | 6.0 | 6.0 | 6.0 | 8 Jul 2025 | 8 Jul 2025 |
| Alpha-GenCASE #VI-2026-0905 | X | 2 | 5.9 | 5.3 | 6.5 | 13 Jun 2025 | 25 May 2026 |
| Anlv BiotechnologyCASE #VI-2026-0110 | X | 1 | 5.7 | 5.7 | 5.7 | 24 Apr 2025 | 24 Apr 2025 |
| Peptide SciencesCASE #VI-2026-0867 | X | 3 | 5.4 | 3.8 | 7.8 | 9 Jun 2025 | 24 May 2026 |
| Hebei Rimao TechnologyCASE #VI-2026-0529 | X | 1 | 5.4 | 5.4 | 5.4 | 9 Jun 2025 | 9 Jun 2025 |
| PurePeptidesCASE #VI-2026-0234 | X | 1 | 5.0 | 5.0 | 5.0 | 16 Mar 2025 | 16 Mar 2025 |
| Qingdao VitaConin International TradingCASE #VI-2026-0504 | X | 1 | 4.8 | 4.8 | 4.8 | 14 Jan 2025 | 14 Jan 2025 |
| Amino AsylumCASE #VI-2026-0828 | X | 1 | 4.7 | 4.7 | 4.7 | 28 Mar 2025 | 28 Mar 2025 |
| Accelerate LabsCASE #VI-2026-0686 | X | 1 | 4.6 | 4.6 | 4.6 | 17 Dec 2024 | 17 Dec 2024 |
| PepKitsCASE #VI-2026-0320 | X | 1 | 0.0 | 0.0 | 0.0 | 21 May 2025 | 21 May 2025 |
Open any subject to view the batch-level evidence for Semaglutide Oral alone.